NewGenIvf Net Income From Continuing Ops from 2010 to 2026
| NIVF Stock | 0.80 0.0001 0.01% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -426.7 K | Current Value -405.4 K | Quarterly Volatility 157.1 K |
Check NewGenIvf Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewGenIvf Group's main balance sheet or income statement drivers, such as Interest Income of 8.4 K, Depreciation And Amortization of 216.5 K or Interest Expense of 940.2 K, as well as many indicators such as Price To Sales Ratio of 27.82, Dividend Yield of 0.0 or Days Sales Outstanding of 80.98. NewGenIvf financial statements analysis is a perfect complement when working with NewGenIvf Group Valuation or Volatility modules.
NewGenIvf | Net Income From Continuing Ops | Build AI portfolio with NewGenIvf Stock |
The Net Income From Continuing Ops trend for NewGenIvf Group Limited offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether NewGenIvf Group is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest NewGenIvf Group's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of NewGenIvf Group Limited over the last few years. It is NewGenIvf Group's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NewGenIvf Group's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
NewGenIvf Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (160,251) | |
| Coefficient Of Variation | (98.06) | |
| Mean Deviation | 97,105 | |
| Median | (138,532) | |
| Standard Deviation | 157,140 | |
| Sample Variance | 24.7B | |
| Range | 609.9K | |
| R-Value | (0.30) | |
| Mean Square Error | 23.9B | |
| R-Squared | 0.09 | |
| Significance | 0.24 | |
| Slope | (9,394) | |
| Total Sum of Squares | 395.1B |
NewGenIvf Net Income From Continuing Ops History
About NewGenIvf Group Financial Statements
NewGenIvf Group stakeholders use historical fundamental indicators, such as NewGenIvf Group's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although NewGenIvf Group investors may analyze each financial statement separately, they are all interrelated. For example, changes in NewGenIvf Group's assets and liabilities are reflected in the revenues and expenses on NewGenIvf Group's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in NewGenIvf Group Limited. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -426.7 K | -405.4 K |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of NewGenIvf Group Correlation against competitors. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Can Health Care Providers & Services industry sustain growth momentum? Does NewGenIvf have expansion opportunities? Factors like these will boost the valuation of NewGenIvf Group. Anticipated expansion of NewGenIvf directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating NewGenIvf Group demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share 4.2 K | Revenue Per Share | Quarterly Revenue Growth (0.13) | Return On Assets | Return On Equity |
Understanding NewGenIvf Group requires distinguishing between market price and book value, where the latter reflects NewGenIvf's accounting equity. The concept of intrinsic value - what NewGenIvf Group's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push NewGenIvf Group's price substantially above or below its fundamental value.
It's important to distinguish between NewGenIvf Group's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NewGenIvf Group should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, NewGenIvf Group's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.